Markus Hartl

Markus Hartl, Ph.D.

Ao. Univ.-Prof. Dr. rer. nat.

Institute of Biochemistry
University of Innsbruck
Room no. L.03.031


Center for Chemistry and Biomedicine (CCB) Innrain 80-82, 6020 Innsbruck / Austria
Phone: +43 512 507 - 57575 | Fax: +43 512 507 - 57599
Email: markus.hartl@uibk.ac.at


Publications 

  1. Hartl M, Willnow T, Fanning, E. cis-active elements from mouse chromosomal DNA suppress simian virus 40 DNA replication.  J Virol. 64, 2884-2894 (1990).
  2. Kazmierczak B, Bartnitzke S, Hartl M, Bullerdiek J. In vitro transformation by the SV40 'early region' of cells from a human benign salivary gland tumor with a 12q13-q15 rearrangement.  Cell Genet. 53, 37-39 (1990).
  3. Hartl M, Hutchins J, Vogt PK. The chicken junD gene and its product. Oncogene 6, 1623-1631 (1991).
  4. Vogt PK., Morgan IM., Havarstein L, Su H, Hartl M, Schuur E. The oncogenicity of Jun. Leukemia 6 Suppl. 3, s184-s186 (1992).
  5. Hartl M, Vogt PK. Oncogenic transfomation by Jun: Role of transactivation and homodimerization. Cell Growth Differ. 3, 899-908 (1992).
  6. Hartl M, Vogt PK. A rearranged JunD transforms chicken embryo fibroblasts. Cell Growth Differ. 3, 909-918 (1992).
  7. Weiskirchen R, Siemeister G, Hartl M, Bister K. Sequence and expression of a glyceraldehyde-3-phosphate dehydrogenase-encoding gene from quail embryo fibroblasts. Gene 128, 269-272 (1993).
  8. Hartl M, Vogt PK, Bister K. A quail long-term cell culture transformed by a chimeric jun oncogene. Virology 207, 321-326 (1995).
  9. Hartl M*, Bister K. Specific activation in jun-transformed avian fibroblasts of a gene (bkj) related to the avian beta-keratin gene family.  Proc. Natl. Acad. Sci. USA 92, 11731-11735 (1995).
  10. Oberst C, Weiskirchen R, Hartl M, Bister K. Suppression in transformed avian fibroblasts of a gene (CO6) encoding a membrane protein related to mammalian potassium channel regulatory subunits. Oncogene 14, 1109-1116 (1997).
  11. Hartl M*, Bister K. Structure and transcriptional regulation of BKJ, a novel AP-1 target gene activated during jun- or fos-induced fibroblast transformation. Oncogene 17, 2901-2913 (1998).
  12. Oberst C, Hartl M, Weiskirchen R, Bister K. Conditional cell transformation by doxycycline-controlled expression of the MC29 v-myc allele. Virology 253, 193-207 (1999).
  13. Bader AG, Hartl M*, Bister K. Conditional cell transformation by doxycycline-controlled expression of the ASV17 v-jun allele. Virology 270, 98-110 (2000).
  14. Bader AG, Schneider ML, Bister K, Hartl M*. TOJ3, a target of the v-Jun transcription factor, encodes a protein with transforming activity related to human microspherule protein 1 (MCRS1). Oncogene 20, 7524-7535 (2001).
  15. Hartl M*, Reiter F, Bader AG, Castellazzi M, Bister K. JAC, a direct target of oncogenic transcription factor Jun, is involved in cell transformation and tumorigenesis. Proc. Natl. Acad. Sci. USA 98, 13601-13606 (2001).
  16. Hartl M*, Bader AG, Bister K. Molecular targets of the oncogenic transcription factor Jun.  Cancer Drug Targets 3, 41-57 (2003).
  17. Hartl M, Matt T, Schüler W, Siemeister G, Kontaxis G, Kloiber K, Konrat R, Bister K. Cell transformation by the v-myc oncogene abrogates c-Myc/Max-mediated suppression of a C/EBPbeta-dependent lipocalin gene.  Mol. Biol. 333, 33-46 (2003).
  18. Hartl M*, Karagiannidis AI, Bister K. Cooperative cell transformation by Myc/Mil(Raf) involves induction of AP-1 and activation of genes implicated in cell motility and metastasis. Oncogene 25, 4043-4055 (2006).
  19. Reiter F, Hartl M, Karagiannidis AI, Bister K. WS5, a direct target of oncogenic transcription factor Myc, is related to human melanoma glycoprotein genes and has oncogenic potential. Oncogene 26, 1769-1779 (2007).
  20. Varela-Nieto I, Hartl M, Gorospe I, Leon Y. Anti-apoptotic actions of insulin-like growth factors: Lessons from development and implications in neoplastic cell transformation.  Pharm. Design 13, 687-703 (2007).
  21. Schedlbauer A, Ozdowy P, Kontaxis G, Hartl M, Bister K, Konrat R. Backbone assignment of osteopontin, a cytokine and cell attachment protein implicated in tumorigenesis.  NMR Assign. 2, 29-31 (2008).
  22. Karagiannidis AI, Bader AG, Hartl M*, Bister K. TOJ3, a v-jun target with intrinsic oncogenic potential, is directly regulated by Jun via a novel AP-1 binding motif. Virology 378, 371–376 (2008).
  23. Hartl M*, Nist A, Khan MI, Valovka T, Bister K. Inhibition of Myc-induced cell transformation by brain acid-soluble protein 1 (BASP1).  Proc. Natl. Acad. Sci. USA 106, 5604-5609 (2009). 
  24. Hartl M, Mitterstiller A, Valovka T, Breuker K, Hobmayer B, Bister K. Stem cell-specific activation of an ancestral mycprotooncogene with conserved basic functions in the early metazoan Hydra.  Proc. Natl. Acad. Sci. USA 107, 4051-4056 (2010).
  25. Coudevylle N, Geist L, Hötzinger M, Hartl M, Kontaxis G, Bister K, Konrat R. The v‑myc-induced Q83 lipocalin is a siderocalin.  Biol. Chem. 285, 41646-41652 (2010).
  26. Aigner M, Hartl M, Fauster K, Steger J, Bister K, Micura R. Chemical synthesis of site-specifically 2'-azido-modified RNA and potential applications for bioconjugation and RNA interference. ChemBioChem 12, 47-51 (2011).
  27. Ganisl B, Valovka T, Hartl M, Taucher M, Bister K, Breuker K. Electron detachment dissociation for top-down mass spectrometry of acidic proteins.  Chemistry 17, 4460-4469 (2011).
  28. Shahnaz G, Hartl M, Barthelmes J, Leithner K, Sarti F, Hintzen F, Rahmat D, Salvenmoser W, Bernkop-Schnürch A. Uptake of phenothiazines by the harvested chylomicrons ex vivo model: influence of self-nanoemulsifying formulation design.  J. Pharm. Biopharm. 79, 171-180 (2011).
  29. Platzer G, Schedlbauer A, Chemelli A, Ozdowy P, Coudevylle N, Auer R, Kontaxis G, Hartl M, Miles AJ, Wallace BA, Glatter O, Bister K, Konrat R. The metastasis-associated extracellular matrix protein osteopontin displays transient structure formation in ligand interaction sites. Biochemistry 50, 6113-6124 (2011).
  30. Coudevylle N, Hoetzinger M, Geist L, Kontaxis G, Hartl M, Bister K, Konrat R. Lipocalin Q83 reveals a dual ligand binding mode with potential implications for the functions of siderocalins. Biochemistry 50, 9192-9199 (2011).
  31. Fauster K, Hartl M, Santner T, Aigner M, Kreutz C, Bister K, Ennifar E, Micura R. 2'‑Azido RNA – a versatile tool for chemical biology: Synthesis, X-ray structure, siRNA applications, and click labeling. ACS Chem. Biol. 7, 581-589 (2012).
  32. Hobmayer B, Jenewein M, Eder D, Eder MK, Glasauer S, Gufler S, Hartl M, Salvenmoser W. Stemness in Hydra– a current perspective.  J. Dev. Biol. 56, 509-517 (2012).
  33. Hartl M, Bister K. Oncogenes. In Brenner's Encyclopedia of Genetics, 2ndedition, Vol 5 (Maloy S, Hughes K, eds), pp. 164-166. Academic Press, San Diego (2013).
  34. Hartl M, Bister K. Analyzing Myc in cell transformation and evolution. In The Myc Gene: Methods and Protocols,Methods in Molecular Biology, Vol. 1012 (Soucek L, Sodir NM, eds), pp. 21-49. Humana Press, New York (2013).
  35. Valovka T, Schönfeld M, Raffeiner P, Breuker K, Dunzendorfer-Matt T, Hartl M, Bister K. Transcriptional control of DNA replication licensing by Myc.  Sci Rep. 3: 3444 (2013). 
  36. Santner T, Hartl M, Bister K, Micura R. Efficient access to 3'-terminal azide-modified RNA for inverse click-labeling patterns. Bioconjugate Chem. 25, 188-195 (2014).
  37. Hartl M*, Glasauer S, Valovka T, Breuker K, Hobmayer B, Bister K. Hydra myc2, a unique pre-bilaterian member of the mycgene family, is activated in cell proliferation and gametogenesis.  Biol Open 3, 397-407 (2014).
  38. Hart JR, Garner AL, Yu J, Ito Y, Sun M, Ueno L, Rhee J-K, Baksh MM, Stefan E, Hartl M, Bister K, Vogt PK, Janda KD. Inhibitor of MYC identified in a Kröhnke pyridine library.  Proc. Natl. Acad. Sci. USA 111, 12556-12561 (2014).
  39. Raffeiner P, Röck R, Schraffl A, Hartl M, Hart JR, Janda KD, Vogt PK, Stefan E, Bister K. In vivoquantification and perturbation of Myc-Max interactions and the impact on oncogenic potential. Oncotarget 5, 8869-8878 (2014).
  40. Jud L, Kosutic M, Schwarz V, Hartl M, Kreutz C, Bister K, Micura R. Expanding the scope of 2'-SCF3 modified RNA.  Chem. Eur. J.  21, 10400-10407 (2015).
  41. Ijaz M, Bonengel S, Zupančič O, Yaqoob M, Hartl M, Hussain S, Huck CW, Bernkop-Schnürch A. Development of oral self nano-emulsifying delivery system(s) of lanreotide with improved stability against presystemic thiol-disulfide exchange reactions. Expert Opin Drug Deliv. 13, 923-929 (2016).
  42. Hartl M*. The quest for targets executing MYC-dependent cell transformation. Front Oncol 6: 132 (2016).
  43. Raffeiner P, Schraffl A, Schwarz T, Röck R, Ledolter K, Hartl M, Konrat R, Stefan E, Bister K. Calcium-dependent binding of Myc to calmodulin. Oncotarget 8, 3327-3343 (2017).
  44. Gufler S, Artes B, Bielen H, Krainer I, Eder MK, Falschlunger J, Bollmann A,  Ostermann T, Valovka T, Hartl M, Bister K, Technau U, Hobmayer B. β-Catenin acts in a position-independent regeneration response in the simple eumetazoan Hydra.  Dev Biol. 433, 310-323 (2018).
  45. Lommel M, Strompen J, Hellewell AL, Balasubramanian GP, Christofidou ED, Thomson AR, Boyle AL, Woolfson DN, Puglisi K, Hartl M, Holstein TW, Adams JC, Özbek S. Hydra mesoglea proteome identifies thrombospondin as a conserved component active in head organizer restriction.  Sci Rep. 8: 11753 (2018).
  46. Hartl M*, Glasauer S, Gufler S, Raffeiner A, Puglisi K, Breuker K, Bister K, Hobmayer B. Differential regulation of mychomologs by Wnt/b-Catenin signaling in the early metazoan Hydra. FEBS J. 286, 2295-2310 (2019).
  47. Hartl M*, Schneider R.  A unique family of neuronal signaling proteins implicated in oncogenesis and tumor suppression.  Front Oncol. 9: 289 (2019).
  48. Hartl M*, Puglisi K, Nist A, Raffeiner P, Bister K. The brain acid-soluble protein 1 (BASP1) interferes with the oncogenic capacity of MYC and its binding to calmodulin. Mol Oncol. 14, 625-644 (2020).
  49. Mayrhofer JE, Enzler F, Feichtner A, Röck R, Fleischmann J, Raffeiner A, Tschaikner P, Ogris E, Huber RG, Hartl M, Scheider R, Troppmair J, Torres-Quesada O, Stefan E (2020): Mutation-oriented profiling of autoinhibitory kinase conformations predicts RAF inhibitor efficacies. Proc. Natl. Acad. Sci. USA 117, 31105 – 31113 (2020).
  50. Mödlhammer A, Pfurtscheller S, Feichtner A, Hartl M*, Schneider R. The diarylheptanoid curcumin induces MYC inhibition and cross-links this oncoprotein to the coactivator TRRAP.  Front. Oncol., 11: 660481 (2021).
  51. Ziegler B, Yiallouros I, Trageser B, Kumar S, Mercker M, Kling S, Fath M, Warnken U, Schnölzer M, Holstein TW, Hartl M, Marciniak-Czochra A, Stetefeld J, Stöcker W, Özbek S. The Wnt-specific astacin proteinase HAS-7 restricts head organizer formation in Hydra. BMC Biol, 19:120 (2021).
  52. Hartl M*, Bister K. MYC analysis in cancer and evolution (chapter 6). In The Myc Gene: Methods and Protocols, Methods in Molecular Biology, Vol 2318 (Soucek L, Whitfield J, eds), pp. 87-117. Humana Press, New York (2021).
  53. Temocin O, Regele D, Sathianathan M, Überbacher C, Hartl M, Edenhofer F, Meyer D. Generation of an hiPSC-1 knock-in line expressing TY1-tagged MNX1-protein together with mScarlet. Stem Cell Res., 56:102522 (2021).
  54. Moreno S, Ramos Pittol JM, Hartl M, Micura R. Robust synthesis of 2’-azido modified RNA from 2’-amino precursors by diazotransfer reaction. Org. Biomol. Chem. 20, 7845-7850  (2022).
  55. Weber LI, Hartl M*. Strategies to target the cancer driver MYC in tumor cells. Front. Oncol. 13:1142111 (2023).
  56. Lechable M, Tang X, Siebert S, Feldbacher A, Fernández-Quintero ML, Breuker K, Juliano CE, Liedl KR, Hobmayer B, Hartl M*. High intrinsic oncogenic potential in the Myc-box-deficient Hydra Myc3 protein. Cells 12, 1265 (2023).
  57. Eichler C, Himmelstoß M, Plangger R, Weber LI, Hartl, M, Kreutz C, Micura R. Advances in RNA labeling with trifluoromethyl groups. Chemistry, e202302220 (2023).

*corresponding author

Nach oben scrollen